A cost-benefit analysis of a National Hypertension Treatment Program in Bangladesh

Preventive Medicine

Volumn 105, Issue , 2017, Pages S56-S61

  Nugent, Rachel ^a   Brower, Elizabeth ^b   Cravioto, Alejandro ^c   Koehlmoos, Tracey ^d  

^a RTI INTERNATIONAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Antihypertensive agents; Bangladesh; Blood pressure; Cardiovascular diseases; Cost benefit analysis; Economic evaluation; Hypertension

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; THIAZIDE DIURETIC AGENT;

ADOLESCENT; ADULT; ARTICLE; BANGLADESH; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG COST; FEMALE; GENDER; GOVERNMENT REGULATION; HEALTH PROGRAM; HUMAN; HYPERTENSION; INCOME; INVESTMENT; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH SERVICE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; PROGRAM COST EFFECTIVENESS; SECONDARY PREVENTION; SEX DIFFERENCE; SOCIOECONOMICS; CEREBROVASCULAR ACCIDENT; HEART INFARCTION; PREVALENCE; PROGRAM EVALUATION; RISK FACTOR; SEX FACTOR;

ADULT; ANTIHYPERTENSIVE AGENTS; BANGLADESH; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; HYPERTENSION; MALE; MYOCARDIAL INFARCTION; PREVALENCE; PROGRAM EVALUATION; RISK FACTORS; SEX FACTORS; STROKE;

EID: 85035029078     PISSN: 00917435     EISSN: 10960260     Source Type: Journal    
DOI: 10.1016/j.ypmed.2017.08.014     Document Type: Article

References (29)

1. Ahsan Karar, Z., Alam, N., Kim Streatfield, P., Epidemiological transition in rural Bangladesh, 1986–2006. Glob. Health Action, 2(1), 2009, 1904.
2. Ahsan, K.Z., Streatfield, P.K., Escudero, G.M., Khan, A.W., Reza, M.M., Fifteen years of sector-wide approach (SWAp) in Bangladesh health sector: an assessment of progress. Health Policy Plan. 31:5 (2016), 612–623.
3. Bangladesh Demographic Health Survey BDHS, NIPORT, Dhaka, Bangladesh. 2013, 2011.
4. Bleich, S.N., Koehlmoos, T.L., Rashid, M., Peters, D.H., Anderson, G., Noncommunicable chronic disease in Bangladesh: overview of existing programs and priorities going forward. Health Policy 100:2 (2011), 282–289.
5. Chowdhury, A.M., Bhuiya, A., Chowdhury, M.E., Rasheed, S., Hussain, Z., Chen, L.C., The Bangladesh paradox: exceptional health achievement despite economic poverty. Lancet 382:9906 (2013 Nov 29), 1734–1745.
6. CUS N. Measure Evaluation, Slums of Urban Bangladesh: Mapping and Census 2005. 2006, Centre for Urban Studies.
7. El-Saharty, S., Ahsan, K.Z., Koehlmoos, T.L., Engelgau, M.M., Tackling Noncommunicable Diseases in Bangladesh: Now is the Time. 2013 Sep 12, World Bank Publications.
8. Gaziano, T.A., Young, C.R., Fitzmaurice, G., Atwood, S., Gaziano, J.M., Laboratory-based versus non-laboratory-based method for assessment of cardiovascular disease risk: the NHANES I Follow-up Study cohort. Lancet 371:9616 (2008), 923–931.
9. Global Health Observatory Data Repository, World Health Organization, Annual Updates. Date accessed: January 1, 2017 http://apps.who.int/gho/data/view.main.60120?lang=en.
10. Hayes, G., Jones, G., The Impact of the demographic transition on socioeconomic development in Bangladesh: Future prospects and implications for public policy. 2015 January 18, The United Nations Population Fund Bangladesh Country Office http://www.plancomm.gov.bd/wp-content/uploads/2015/02/22_Impact-of-Demographic-Transition-on-Socioeconomic-Development.pdf.
11. Hypertension Study Group, Prevalence, awareness, treatment and control of hypertension among the elderly in Bangladesh and India: a multicentre study. Bull. World Health Organ., 79(6), 2001, 490.
12. James, P.A., Oparil, S., Carter, B.L., Cushman, W.C., Dennison-Himmelfarb, C., Handler, J., Lackland, D.T., LeFevre, M.L., MacKenzie, T.D., Ogedegbe, O., Smith, S.C., 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311:5 (2014 Feb 5), 507–520.
13. Jamison, D.T., Breman, J.G., Measham, A.R., Alleyne, G., Claeson, M., Evans, D.B., Jha, P., Mills, A., Musgrove, P., Disease Control Priorities in Developing Countries. 2006, World Bank Publications.
14. Kotseva, Kornelia et al., Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 373:9667 (2009), 929–940.
15. Mancia, G., Fagard, R., Narkiewicz, K., Redon, J., Zanchetti, A., Bohm, M. et al., ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur. Heart J. 34 (2013), 2159–2219.
16. Murray, C.J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A.D., Michaud, C., Ezzati, M., Shibuya, K., Salomon, J.A., Abdalla, S., Aboyans, V., Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:9859 (2013 Jan 4), 2197–2223.
17. Ngalesoni, F.N., Ruhago, G.M., Mori, A.T., Robberstad, B., Norheim, O.F., Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study. BMC Health Serv. Res., 16(1), 2016 May 17, 185.
18. Nugent, R., Brouwer, E., Economic benefit-cost analysis of select secondary prevention interventions in LMIC. Glob. Heart 10:4 (2015 Dec 31), 319–321.
19. rd Edition, 2017, World Bank (forthcoming).
20. Razzaque, A., Nahar, L., Mustafa, A.H., Ahsan, K.Z., Islam, M.S., Yunus, M., Sociodemographic differentials of selected noncommunicable diseases risk factors among adults in Matlab, Bangladesh: findings from a WHO STEPS survey. Asia Pac. J. Public Health 23:2 (2011 Mar 1), 183–191.
21. Sayeed, M.A., Banu, A., Haq, J.A., Khanam, P.A., Mahtab, H., Azad, K.A., Prevalence of hypertension in Bangladesh: effect of socioeconomic risk factor on difference between rural and urban community. Bangladesh Med. Res. Counc. Bull. 28:1 (2002 Apr), 7–18.
22. Statistics BBo, Health and Morbidity Status Survey- 2012. 2013, Bangladesh Bureau of Statistics.
23. Streatfield, P.K., Karar, Z.A., Population challenges for Bangladesh in the coming decades. J. Health Popul. Nutr. 1 (2008 Sep), 261–272.
24. Viswanathan, M., Golin, C.E., Jones, C.D., Ashok, M., Blalock, S.J., Wines, R.C. et al., Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann. Intern. Med., 157, 2012, 78595.
25. World Health Organization, Global Health Estimates: Deaths by Cause, Age, Sex and Country. 2014, 2000-2012, WHO, Geneva, 7.
26. World Health Organization, A Global Brief on Hypertension: Silent Killer, Global Public Health Crisis. http://apps.who.int/iris/bitstream/10665/79059/1/WHO_DCO_WHD_2013.2_eng.pdf, 2013.
27. Yusuf, S., Two decades of progress in preventing vascular disease. Lancet 360:9326 (2002 Jul 6), 2–3.
28. Yusuf, S., Islam, S., Chow, C.K., Rangarajan, S., Dagenais, G., Diaz, R., Gupta, R., Kelishadi, R., Iqbal, R., Avezum, A., Kruger, A., Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE study): a prospective epidemiological survey. Lancet 378:9798 (2011 Oct 7), 1231–1243.
29. Zaman, M.M., Rouf, M.A., Prevalence of hypertension in a Bangladeshi adult population. J. Hum. Hypertens. 13:8 (1999 Jul), 547–549.